217 related articles for article (PubMed ID: 16423429)
1. Serological response to pneumococcal vaccination in HAART-treated HIV-infected patients: one year follow-up study.
Falcó V; Jordano Q; Cruz MJ; Len O; Ribera E; Campins M; Crespo M; Ocaña I; Rodrigo MJ; Pahissa A
Vaccine; 2006 Mar; 24(14):2567-74. PubMed ID: 16423429
[TBL] [Abstract][Full Text] [Related]
2. Clinical experience of the 23-valent capsular polysaccharide pneumococcal vaccination in HIV-1-infected patients receiving highly active antiretroviral therapy: a prospective observational study.
Hung CC; Chen MY; Hsieh SM; Hsiao CF; Sheng WH; Chang SC
Vaccine; 2004 May; 22(15-16):2006-12. PubMed ID: 15121313
[TBL] [Abstract][Full Text] [Related]
3. A 5-year longitudinal follow-up study of serological responses to 23-valent pneumococcal polysaccharide vaccination among patients with HIV infection who received highly active antiretroviral therapy.
Hung CC; Chang SY; Su CT; Chen YY; Chang SF; Yang CY; Liu WC; Wu CH; Chang SC
HIV Med; 2010 Jan; 11(1):54-63. PubMed ID: 19659943
[TBL] [Abstract][Full Text] [Related]
4. The immunogenicity and safety of pneumococcal conjugate vaccine in human immunodeficiency virus-infected Thai children.
Thanee C; Pancharoen C; Likitnukul S; Luangwedchakarn V; Umrod P; Phasomsap C; Apornpong T; Chuanchareon T; Butterworth O; Puthanakit T
Vaccine; 2011 Aug; 29(35):5886-91. PubMed ID: 21729732
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy.
Abzug MJ; Pelton SI; Song LY; Fenton T; Levin MJ; Nachman SA; Borkowsky W; Rosenblatt HM; Marcinak JF; Dieudonne A; Abrams EJ; Pathak I;
Pediatr Infect Dis J; 2006 Oct; 25(10):920-9. PubMed ID: 17006288
[TBL] [Abstract][Full Text] [Related]
6. Response of human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy to vaccination with 23-valent pneumococcal polysaccharide vaccine.
Rodriguez-Barradas MC; Alexandraki I; Nazir T; Foltzer M; Musher DM; Brown S; Thornby J
Clin Infect Dis; 2003 Aug; 37(3):438-47. PubMed ID: 12884170
[TBL] [Abstract][Full Text] [Related]
7. A case-control study to investigate serological correlates of clinical failure of 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults.
French N; Moore M; Haikala R; Kayhty H; Gilks CF
J Infect Dis; 2004 Aug; 190(4):707-12. PubMed ID: 15272398
[TBL] [Abstract][Full Text] [Related]
8. Pneumonia in HIV-infected patients in the HAART era: incidence, risk, and impact of the pneumococcal vaccination.
López-Palomo C; Martín-Zamorano M; Benítez E; Fernández-Gutiérrez C; Guerrero F; Rodríguez-Iglesias M; Girón-González JA
J Med Virol; 2004 Apr; 72(4):517-24. PubMed ID: 14981752
[TBL] [Abstract][Full Text] [Related]
9. Comparison of serologic responses to vaccination with one dose or two doses of 7-valent pneumococcal conjugate vaccine in HIV-infected adult patients.
Lu CL; Hung CC; Chuang YC; Liu WC; Su CT; Hsiao CF; Tseng YT; Su YC; Chang SF; Chang SY; Chang SC
Vaccine; 2012 May; 30(24):3526-33. PubMed ID: 22484349
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity of 23-valent pneumococcal polysaccharide vaccine in children with human immunodeficiency virus undergoing highly active antiretroviral therapy.
Tangsinmankong N; Kamchaisatian W; Day NK; Sleasman JW; Emmanuel PJ
Ann Allergy Asthma Immunol; 2004 May; 92(5):558-64. PubMed ID: 15191025
[TBL] [Abstract][Full Text] [Related]
11. Induction of opsonophagocytic killing activity with pneumococcal conjugate vaccine in human immunodeficiency virus-infected Ugandan adults.
Chen M; Ssali F; Mulungi M; Awio P; Yoshimine H; Kuroki R; Furumoto A; Tanimura S; Kityo C; Nagatake T; Mugyenyi P; Oishi K
Vaccine; 2008 Sep; 26(38):4962-8. PubMed ID: 18639599
[TBL] [Abstract][Full Text] [Related]
12. Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults.
Lesprit P; Pédrono G; Molina JM; Goujard C; Girard PM; Sarrazin N; Katlama C; Yéni P; Morineau P; Delfraissy JF; Chêne G; Lévy Y;
AIDS; 2007 Nov; 21(18):2425-34. PubMed ID: 18025879
[TBL] [Abstract][Full Text] [Related]
13. Improving the immunogenicity of pneumococcal conjugate vaccine in HIV-infected adults with a toll-like receptor 9 agonist adjuvant: a randomized, controlled trial.
Søgaard OS; Lohse N; Harboe ZB; Offersen R; Bukh AR; Davis HL; Schønheyder HC; Østergaard L
Clin Infect Dis; 2010 Jul; 51(1):42-50. PubMed ID: 20504165
[TBL] [Abstract][Full Text] [Related]
14. Conjugate pneumococcal vaccine in HIV-infected Ugandans and the effect of past receipt of polysaccharide vaccine.
Miiro G; Kayhty H; Watera C; Tolmie H; Whitworth JA; Gilks CF; French N
J Infect Dis; 2005 Nov; 192(10):1801-5. PubMed ID: 16235180
[TBL] [Abstract][Full Text] [Related]
15. Qualitative change in antibody responses of human immunodeficiency virus-infected individuals to pneumococcal capsular polysaccharide vaccination associated with highly active antiretroviral therapy.
Subramaniam KS; Segal R; Lyles RH; Rodriguez-Barradas MC; Pirofski LA
J Infect Dis; 2003 Mar; 187(5):758-68. PubMed ID: 12599049
[TBL] [Abstract][Full Text] [Related]
16. Serological response to 13-valent pneumococcal conjugate vaccine in children and adolescents with perinatally acquired HIV infection.
Bamford A; Kelleher P; Lyall H; Haston M; Zancolli M; Goldblatt D; Kampmann B
AIDS; 2014 Sep; 28(14):2033-43. PubMed ID: 25222526
[TBL] [Abstract][Full Text] [Related]
17. Pneumococcal conjugate vaccination in persons with HIV: the effect of highly active antiretroviral therapy.
Søgaard OS; Schønheyder HC; Bukh AR; Harboe ZB; Rasmussen TA; Ostergaard L; Lohse N
AIDS; 2010 Jun; 24(9):1315-22. PubMed ID: 20559037
[TBL] [Abstract][Full Text] [Related]
18. Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunodeficient virus infected and non-infected children in the absence of a booster dose of vaccine.
Madhi SA; Adrian P; Kuwanda L; Jassat W; Jones S; Little T; Soininen A; Cutland C; Klugman KP
Vaccine; 2007 Mar; 25(13):2451-7. PubMed ID: 17023095
[TBL] [Abstract][Full Text] [Related]
19. Persistence of antibody response to pneumococcal capsular polysaccharides in vaccinated long term-care residents in Brazil.
Brandão AP; de Oliveira TC; de Cunto Brandileone MC; Gonçalves JE; Yara TI; Simonsen V
Vaccine; 2004 Dec; 23(6):762-8. PubMed ID: 15542200
[TBL] [Abstract][Full Text] [Related]
20. Circulating memory B-cell subpopulations are affected differently by HIV infection and antiretroviral therapy.
D'Orsogna LJ; Krueger RG; McKinnon EJ; French MA
AIDS; 2007 Aug; 21(13):1747-52. PubMed ID: 17690573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
